Hemophilia Gene Therapy Studies Could Use Non-Inferiority Design, US FDA Suggests
Development guidance from CBER recommends comparing investigational gene therapy products to existing prophylaxis treatment.
Development guidance from CBER recommends comparing investigational gene therapy products to existing prophylaxis treatment.